logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: News & Comments

Celgene has important CAR T presentations at ASH

At the 60th American Society of Hematology (ASH)  Annual Meeting    CAR T is Still a Star With all the pessimistic views critics have sprayed around in the past few years about the cell therapy for cancer, the CAR T...

Read More

December 4, 2018

0

The FDA New Guidelines to Speed the Approval of Gene Therapy. See Also: The Gene Editing Effect

Important news has come from the FDA, which issued new guidelines to speed the introduction of treatments with human cells and tissues, including gene therapy. Cracking down on rogue clinics offering dangerous or unproven versions of gene therapy or stem...

Read More

November 17, 2017

0

The FDA Approved AMAG Pharmaceuticals' Product Vyleesi™ for Premenopausal Women with Acquired Generalized Hypoactive Sexual Desire Disorder

AMAG Pharmaceuticals' Vyleesi™ was Approved The U.S. Food and Drug Administration (FDA) approved AMAG Pharmaceuticals’ ( AMAG )  product Vyleesi (bremelanotide injection); a melanocortin receptor agonist for premenopausal women having acquired, generalized hypoactive sexual desire disorder (HSDD)   To be...

Read More

June 24, 2019

0

Exelixis initiates a phase 3 trial with cabozantinib combination for previously untreated liver cancer

Exelixis (EXEL) and  Ipsen (Euronext: IPN; ADR: IPSEY)   announced the initiation of COSMIC-312. A phase 3 pivotal trial of cabozantinib (CABOMETYX ® ) in combination with atezolizumab (T ECENTRIQ ® ) versus sorafenib, in previously untreated advanced hepatocellular carcinoma ( H...

Read More

December 6, 2018

0

A New Trial Demonstrates Promising Results of CAR T Targeting CD-22 for Leukemia Patients.

The Treatment is Not A New Way as Being Stated, It is Only the Target, Which Has Been Changed   Outstanding news announced that leukemia patients who relapsed after being treated with the chimeric receptor antigen T cell (CAR T)...

Read More

November 21, 2017

0

ImmunoGen: Experiencing Big Internal Changes

ImmunoGen's Big Internal Changes ImmunoGen ( IMGN )   announced a radical impacting decision following the completion of an in-depth operational review aimed at extending the Company’s cash runway; delivering on its promises to continue developing a promising antibody drug...

Read More

June 28, 2019

0

Gilead to File NDA for Rheumatoid Arthritis Drug Filgotinib. Karyopharm Stock Gained 36% in Today's Trading

Gilead to File NDA for Filgotinib for Rheumatoid Arthritis Meeting with the U.S. Food and Drug Administration (FDA)   Gilead ( GILD )   announced it discussed with the agency the Phase 3 FINCH studies;  as well as the ongoing...

Read More

July 3, 2019

0

Practicing More Personalized Medicine

All the necessities, including future plans, are being taken care of by institutions, academia and biotech companies that are increasingly offering the medical community what they need to treat diseases based on their genetic mutations, if any. In recent news,...

Read More

December 5, 2017

0

A follow up on Gilead's latest news

The Chinese National Medical Products Administration  (NMPA) has approved Gilead’s (GILD) HIV combination product Descovy ®.  In China, Descovy is to be indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) in adults and...

Read More

December 12, 2018

0

Regeneron's Product Libtayo is Unique and Expected to Become a Best-Seller

The EC Granted Conditional Approval for Regeneron and Sanofi Product Libtayo for CSCC The European Commission ( EC ) conditional approval for Regeneron Pharmaceuticals’  ( REGN ) and   Sanofi’s  ( SNY )   product  Libtayo ® (cemiplimab)  is a historical...

Read More

July 9, 2019

0

  • Previous
  • 1
  • 2
  • ...
  • 60
  • 61
  • 62
  • ...
  • 115
  • 116
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy